Lineage Announces a Grand Prize of $50,000 for the Food Chain Innovation Challenge
5.9.2024 15:31:00 EEST | Business Wire | Press release
Lineage, Inc. (NASDAQ: LINE) (the “Company”), the world’s largest global temperature-controlled warehouse REIT, today announced additional details of its flagship competition, the Food Chain Innovation Challenge, including members of the judging panels as well as the grand prize.
The challenge of creating impactful solutions for food waste comes at a critical time, as the severely food-insecure population is expected to hit nearly a billion people by 2028. Lineage’s global competition invites students and startups to pitch their innovative technologies or data solutions that address postharvest food waste.
The Food Chain Innovation Challenge will take place in three major locations: London on November 14, and Amsterdam and San Francisco both on November 19. Students, startups and other relevant candidates interested in participating can submit their applications online until September 30.
During each event, participants will present solutions aimed at mitigating food waste to an esteemed regional judging panel. Judges will select a regional winner, who will be awarded a $5,000 cash prize and a spot in the grand final event on December 2. One winner will then be chosen to receive the $50,000 grand prize and an invite into a six-month, executive-led incubator program tailored to their unique business goals.
London
The London event will take place on November 14, 2024, at The Science Museum. Lineage’s Regional Vice President, Clare Walters, will join a panel of distinguished judges including Simon Millard, Director of Food at FareShare; Harriet Lamb, CEO of WRAP; and Paul Randle, from the Cambridge Institute for Sustainable Leaders at Cambridge University. To support the aspiring innovators, ReLondon and FoodCycle are also partnering with the Food Chain Innovation Challenge to provide valuable insights and coaching as applicants refine their pitches.
Amsterdam
The Amsterdam event will take place on November 19, 2024, at The NEMO Science Museum. Lineage’s European President, Harld Peters, will join a panel of distinguished judges including Toine Timmermans, Director of Samen Tegen Voedselverspilling; Enno Masurel, Professor Doctor of Sustainable Entrepreneurship at the Free University Amsterdam; and Esteban Arriaga, CEO of FEBA (European Food Banks Federation).
San Francisco
The San Francisco event will take place on November 19, 2024, at the California Academy of Sciences. Lineage’s Global Chief Operations Officer Jeff Rivera will join a panel of distinguished judges, including Angel Veza, Capital, Innovation, & Engagement Senior Manager at ReFED; Danielle Todd, Founder and Executive Director at Make Food Not Waste; and Michael Wara, Director, Climate and Energy Policy Initiative at Stanford's Woods Institute for the Environment and Senior Director, Policy at the Sustainability Accelerator within the Stanford Doerr School of Sustainability.
Greg Lehmkuhl, President and CEO of Lineage, said: “Lineage is constantly looking at how we improve the global management of food storage, transportation and distribution. Beyond our own operational improvements, the Food Chain Innovation Challenge is a platform for us to support the industry's most promising talent and innovations. By collaborating, we can develop solutions that not only address food waste but also promote sustainable practices for the long term.”
Jeff Rivera, Global Chief Operations Officer at Lineage, added: “Despite producing enough food to feed the planet, hundreds of millions of people face food insecurity every day. At Lineage, we're dedicated to transforming the food supply chain to eliminate waste and feed the world. The Food Chain Innovation Challenge exemplifies this mission, and we’re excited to highlight new solutions and innovations while supporting these entrepreneurs' journeys to turn their ideas into reality.”
At the events, participants will be asked to pitch their existing ideas across four specific areas: reducing food waste, food preservation techniques, access to nutritious food and data-driven insights and analytics.
If you're interested in participating, apply here. For a glimpse into the 2023 Hackathon, the predecessor to The Food Chain Innovation Challenge held in Amsterdam, watch this video. Also, hear insights from last year's winner to get inspired and understand the impact of winning this prestigious challenge.
About Lineage
Lineage, Inc. (NASDAQ: LINE) is the world’s largest global temperature-controlled warehouse REIT with a network of over 480 strategically located facilities totaling over 84 million square feet and approximately 3.0 billion cubic feet of capacity across countries in North America, Europe, and Asia-Pacific. Coupling end-to-end supply chain solutions and technology, Lineage partners with some of the world’s largest food and beverage producers, retailers, and distributors to help increase distribution efficiency, advance sustainability, minimize supply chain waste, and, most importantly, feed the world. Learn more at onelineage.com and join us on LinkedIn, Facebook, Instagram, and X.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240905272650/en/
Contacts
Media Contact
Christina Wiese
Public Relations Manager
cwiese@onelineage.com
734-608-1855
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom